Evidence map›Paper›PMID 36980597›Full record

ArticleCancers2023

Impact of Hormone Replacement Therapy on Risk of Ovarian Cancer in Postmenopausal Women with De Novo Endometriosis or a History of Endometriosis.

Hee Joong Lee, Banghyun Lee, Hangseok Choi, Taehee Kim, Yejeong Kim, Yong Beom Kim

Open access · goldFull text read
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Is HRT a trigger for cancer in postmenopausal patients with a history of endometriosis?Journal of the Turkish German Gynecological Association · 2025
    Article
  2. Review
  3. Review
  4. Assessment of knowledge and awareness about ovarian cancer and its risk factors among women in Jazan, Saudi Arabia: a cross-sectional study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025
    Article
  5. Management of menopause in women with a history of endometriosis.Journal of the Turkish German Gynecological Association · 2024
    Article
  6. Review
  7. Immune pathway through endometriosis to ovarian cancer.World journal of clinical oncology · 2024
    Review
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Hee Joong LeeDepartment of Obstetrics & Gynecology, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Uijeongbu-si 11765, Gyeonggi-do, Republic of Korea.
Banghyun LeeDepartment of Obstetrics and Gynecology, Inha University Hospital, College of Medicine, Inha University, 27, Inhang-ro, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.ORCID 0000-0003-1036-3828
Hangseok ChoiMedical Science Research Center, College of Medicine, Korea University, 73, Goryeodae-ro, Seongbuk-gu, Seoul 02841, Republic of Korea.ORCID 0000-0001-7412-8160
Taehee KimDepartment of Obstetrics and Gynecology, Inha University Hospital, College of Medicine, Inha University, 27, Inhang-ro, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
Yejeong KimDepartment of Obstetrics and Gynecology, Inha University Hospital, College of Medicine, Inha University, 27, Inhang-ro, Sinheung-dong, Jung-gu, Incheon 22332, Republic of Korea.
Yong Beom KimDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82, Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si 13620, Gyeonggi-do, Republic of Korea.ORCID 0000-0003-1196-369X
Inha University Hospital · KRSeoul National University Bundang Hospital · KRKorea University Medical Center · KRThe Catholic University of Korea Uijeongbu St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of hormone replacement therapy (HRT) on the malignant transformation of postmenopausal endometriosis remains unclear. This study aimed to investigate the impact of HRT on ovarian cancer occurrence in postmenopausal women with de novo endometriosis or a history of endometriosis. A total of 10,304 women that received HRT (the HRT group) and 10,304 that did not (the control group) were selected by 1:1 matching those that met the study criteria. Incidences of ovarian cancer (0.3% in the HRT group and 0.5% in the control group) and cumulative incidence rates of ovarian cancer were similar in the two groups. The overall mean duration of HRT was 1.4 ± 2.2 years, but the duration of HRT in women with ovarian cancer was 2.2 ± 2.9 years. After adjusting for co-variables, receipt of HRT, duration of HRT, combined use of estrogen and progesterone, and tibolone were not found to be risk factors for ovarian cancer. However, the use of estrogen alone was found to be a significant risk factor for ovarian cancer (HR 2.898; 95% CI 1.251-6.715;

Indexed as

endometriosishormone replacement therapyovarian cancerpost-menopause

Identifiers

PMID36980597
PMCPMC10046182
OpenAlexW4324066577

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read24
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.